Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evofosfamide + Pemetrexed in 2nd-line Non-Squamous NSCLC
NCT02093962Phase 2Terminated
- Sponsor
- ImmunoGenesis
- Start
- Jun 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing TH-302 + Pemetrexed with Placebo + Pemetrexed (2 arms). Primary endpoint: Overall Survival at 2 years. Started Jun 2014; status: terminated.
02
Drugs
evofosfamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02093962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093962.